Head-To-Head Review: Oruka Therapeutics (NASDAQ:ORKA) & Clearmind Medicine (NASDAQ:CMND)

Clearmind Medicine (NASDAQ:CMND) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Profitability

This table compares Clearmind Medicine and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-207.53%	-100.70%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Risk and Volatility

Clearmind Medicine has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500.

Earnings & Valuation

This table compares Clearmind Medicine and Oruka Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86 million	($19.72)	-0.05
Oruka Therapeutics	N/A	N/A	-$105.43 million	($1.86)	-28.66

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Clearmind Medicine and Oruka Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0	0	0	0	0.00
Oruka Therapeutics	1	0	10	0	2.82

Oruka Therapeutics has a consensus price target of $59.60, indicating a potential upside of 11.80%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Clearmind Medicine.

Insider and Institutional Ownership

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Oruka Therapeutics beats Clearmind Medicine on 7 of the 11 factors compared between the two stocks.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.